Translational multimodality neuroimaging

Current Drug Targets

Volumn 18, Issue 9, 2017, Pages 1039-1050

  Sharma, Sushil ^a  

^a SAINT JAMES SCHOOL OF MEDICINE   (Anguilla)

Author keywords

Computerized tomography (CT); Magnetic resonance imaging (MRI); Magnetic resonance spectroscopy (MRS); Nanoparticles; Personalized theranostics; Positron emission tomography (PET); Radiopharmaceuticals; Ultrasound imaging

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE RECEPTOR; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; NICOTINIC RECEPTOR; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; ZIRCONIUM; GLUCOSE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN BLOOD FLOW; BRAIN DAMAGE; BRAIN PERFUSION; BRAIN REGION; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DEPENDENCE; GENE MAPPING; GLIOMA; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; NEUROIMAGING; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; ANIMAL; BRAIN; C57BL MOUSE; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; METABOLISM; MOUSE; MULTIMODAL IMAGING; RADIATION RESPONSE; RADIOASSAY;

ANIMALS; APOPTOSIS; BRAIN; CENTRAL NERVOUS SYSTEM INFECTIONS; GLUCOSE; HUMANS; MICE; MICE, INBRED C57BL; MULTIMODAL IMAGING; NEURODEGENERATIVE DISEASES; RADIOLIGAND ASSAY; RECEPTORS, NICOTINIC; STEM CELL TRANSPLANTATION; SUBSTANCE-RELATED DISORDERS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85022188942     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450118666170315111542     Document Type: Article

References (81)

1. Roccaa WA, Petersen RC, Knopmanb DS, et al. Trends in the incidence and prevalence of Alzheimer’s disease, dementia, and cognitive impairment in the United States. Alzheimers Dement 2011; 7: 80-93.
2. Qiu C, Kivipelto M, Strauss EV. Epidemiology of Alzheimer’s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 2009; 11: 111-28.
3. Shulman JM, De Jager PL, Feany MB. "Parkinson's disease: genetics and pathogenesis". Annu Rev Pathol 2011; 6: 193-222.
4. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropa-thological Alterations in Alzheimer Disease Eds: Selkoe DJ, Holtzman DM, and Mandelkow E. Cold Spring Harb Perspect Med 2011; 1: a006189.
5. Lacor PN. Advances on the Understanding of the Origins of Synaptic Pathology in AD. Curr Genomics 2007; 8: 486-508.
6. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-β immunotherapy? Nat Rev Neurol 2010; 6: 108-19.
7. Danysz W, Parsons CG. Alzheimer’s disease, b-amyloid, glutamate, NMDA receptors and memantine - searching for the connections. Br J Pharmacol 2012; 167: 324-52.
8. Mokhtar, SH, Bakhuraysah MM, Cram DS, Petratos S. The Beta-amyloid protein of Alzheimer’s disease: communication break- down by modifying the neuronal cytoskeleton. Int J Alzheimers Dis 2013; 2013: 910502.
9. Nasrallah IM, Wolk DA. Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias J Nucl Med 2014; 55: 2003-11.
10. Harvey PD. Clinical applications of neuropsychological assessment. Dialogues Clin Neurosci 14; 2012: 91-9.
11. Brenner LA. Neuropsychological and neuroimaging findings in traumatic brain injury and post-traumatic stress disorder. Dialogues Clin Neurosci 2011; 13: 311-23.
12. Chang CC, Lui CC, Wang JJ, et al. Multi-parametric neuroimaging evaluation of cerebrotendinous xanthomatosis and its correlation with neuropsychological presentations. BMC Neurology 2010; 10: 1-8.
13. Liu S, Cai W, Liu S, et al. Multimodal neuroimaging computing: a review of the applications in neuropsychiatric disorders. Brain Informatics 2015; 2: 167-80.
14. Albert M, DeCarli C, DeKosky S, et al. The Use of MRI and PET for clinical diagnosis of dementia and investigation of cognitive impairment: a consensus report prepared by the neuroimaging work group1 of the Alzheimer’s association 2015, pp 1-15.
15. Eshaghia A, Riyahi-Alama, S, Saeedia R, et al. Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis. NeuroImage Clinical 2015; 7: 306-14.
16. Schillaci O, Travascio L, Bruni C, et al. Molecular imaging and magnetic resonance imaging in early diagnosis of Alzheimer's disease. A literature review. Neuroradiol J 2009; 21: 755-71.
17. Gueguen B, Touchon J, Campion D. Memory disorders in the elderly: complementary examinations--for whom?. Therapie 1997; 52: 499-02.
18. Sharma S, Ebadi M. SPECT Neuroimaging in Translational Research of CNS Disorders. Neurochem Internat 2008; 52: 352-62.
19. Liu S, Pan Y, Lv J, Wu H, Tian J, Zhang Y. Feasibility of baculovi-rus-mediated reporter gene delivery for efficient monitoring of islet transplantation in vivo. Nucl Med Biol 2014; 41(2): 171-8.
20. John AE, Luckett JC, Tatler AL, et al. Preclinical SPECT/CT imaging of αvβ6 integrins for molecular stratification of idiopathic pulmonary fibrosis. J Nucl Med 2013; 54: 2146-52.
21. Furka I, Németh N, Mikó I. The spleen in experimental surgery. Magy Seb 2013; 66: 156-160.
22. Skaliczki G, Weszl M, Schandl K, et al. Compromised bone healing following spacer removal in a rat femoral defect model. Acta Physiol Hung 2012; 99: 223-32.
23. Pan Y, Liu S, Wu H, Lv J, Xu X, Zhang Y. Baculovirus as an ideal radionuclide reporter gene vector: a new strategy for monitoring the fate of human stem cells in vivo. PLoS One 2013; 8: e61305.
24. Polyák A, Hajdu I, Bodnár M, et al. (99m)Tc-labelled nanosystem as tumour imaging agent for SPECT and SPECT/CT modalities. Int J Pharm 2013; 449: 10-17.
25. Lin KJ, Wu CC, Pan YH, et al. In vivo imaging of radiation-induced tissue apoptosis by (99m)Tc(I)-his (6)-annexin A5. Ann Nucl Med 2012; 26: 272-80.
26. 18 F-FDG. Curr Radiopharm 2011; 4: 5-9.
27. Kersemans V, Thompson J, Cornelissen B, et al. Micro-CT for anatomic referencing in PET and SPECT: radiation dose, biologic damage, and image quality. J Nucl Med 2011; 52: 1827-33.
28. 18F PET and 99mTc SPECT imaging in phantoms and in tumored mice. Bioconjug Chem 2010; 21; 1565-70.
29. Cheng D; Rusckowski M, Pretorius PH, et al. Improving the quantitation accuracy in noninvasive small animal single photon emission computed tomography imaging. Nucl Med Biol 2011; 38: 843-48.
30. Liang M, Liu X, Cheng D, et al. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjug Chem 2010; 21: 1385-8.
31. Mathe D, Balogh Polyak A, Keraly R, et al. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol 2010; 37: 215-26.
32. von Guggenberg E, Sallegger W, Helbok A, et al. Cyclic Minigas-trin analogs for gastrin receptor scintigraphy with Technetium-99m: preclinical evaluation. J Med Chem 2009; 52: 4786-93.
33. Garrood T, Blades M, Haskard DO, Mather S, Pitzalis C. A novel model for the pre-clinical imaging of inflamed human synovial vasculature. von Guggenberg. Rheumatology (Oxford) 2009; 48: 926-31.
34. Shyam babu C, Satishchandra P, Mahadevan A, et al. Usefulness of stereotactic biopsy and neuroimaging in management of HIV-1 Clade C associated focal brain lesions with special focus on cerebral toxoplasmosis. Clin Neurol Neurosurg 2013; 115: 995-02.
35. Saricicek A, Esterlis I, Maloney KH, et al. Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry 2012; 169: 851-9.
36. Manzardo C, Del Mar Ortega M, Sued O, García F, Moreno A, Miró JM. Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. J Neurovirol 2005; Suppl 3: 72-82.
37. Gualdi GF, Colaiacomo MC, Bertini L, Melone A, Rojas M, Di Biasi C. Neuroimaging of Alzheimer disease: current role and future potential. Clin Ter 2004; 155: 429-38.
38. 18F-FDG PET/CT scan. Rev Esp Med Nucl 2011; 30: 301-6.
39. Chabenne A, Moon C, Ojo C, Khogali A, Nepal B, Sharma S. Biomarkers in Fetal Alcohol Syndrome (Recent Update). Biomarkers and Genomic Medicine 2014; 6: 12-22.
40. Sharma S, Gawande S, Jagtap A, Abeulela R, and Salman Z. Fetal Alcohol Syndrome; Prevention, Diagnosis, & Treatment. In Alcohol Abuse: Prevalence, Risk Factors. Nova Science Publishers, New York, U.S.A. Ed Jeffrey Raines, Chapter 3, pp 39-94.
41. Sharma S, Ebadi M. Charnoly body as a Universal Biomarker of Cell Injury. Biomarkers and Genomic Medicine 2014; 6: 89-98.
42. Sharma S. (2014) Molecular Pharmacology of Environmental Neu-rotoxins. In Kainic Acid: Neurotoxic Properties, Biological Sources, and Clinical Applications. Nova Science Publishers. New York P1-47.
43. Sharma S, Ebadi M. Significance of Metallothioneins in Aging Brain. Neurochem Int 2014; 65: 40-48.
44. Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, Jelebinkov M, Kurdi Y, Ebadi M. Biomarkers of Parkinson’s Disease (Recent Update). Neurochem Int 2013; 63: 201-29.
45. Sharma S, Rais A, Sandhu R, Nel W, Manuchair Ebadi. Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomedicine 2013: 8 1477-88.
46. 18F-DOPA in Weaver Mutant Mice. Brain Res Mol Brain Res 2005; 139: 23-30.
47. 10. Brain Res Bull 2006; 70: 22-32.
48. Ebadi M, Sharma S. Metallothioneins 1 and 2 Attenuate Peroxyni-trite-Induced Oxidative Stress in Parkinson’s disease. Exp Biol Med (Maywood) 2006; 231(9): 1576-83.
49. Sharma S, Ebadi M. In-Vivo Molecular Imaging in Parkinson’s Disease. In Parkinson’s Disease. Eds. RF. Pfeiffer, ZK Wszolek, M. Ebadi. IInd Edition, Chapter 58, CRC Press Taylor & Francis Group. Boca Rotan, FL, USA. 2013, pp. 787-802
50. Sharma S, Ebadi M. Antioxidant Targeting in Neurodegenerative Disorders. Ed. I. Laher, Springer Verlag. Germany. 2014, Chapter 85, p 1-30.
51. Desmyter S, van Heeringen C, Audenaert K. Structural and functional neuroimaging studies of the suicidal brain. Prog Neuropsy-chopharmacol Biol Psychiatry 2011; 35: 796-808.
52. Erritzoe D, Talbot P, Frankle WG, Abi-Dargham A. Positron emission tomography and single photon emission CT molecular imaging in schizophrenia. Neuroimaging Clin N Am 2003; 13: 817-32.
53. Seibyl JP. Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders. Semin Nucl Med 2008; 38: 274-86.
54. Morano GN, Seibyl JP. Technical overview of brain SPECT imaging: improving acquisition and processing of data. J Nucl Med Technol 2003; 31: 191-5.
55. Anonmous. Iometopane: (123)I beta-CIT, dopascan injection, GPI 200, RTI 55. Drugs R D. 2003; 4: 320-22.
56. Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia. sensitivity and specificity of regional cerebral metabolic and other parameters for early identifi- cation of Alzheimer's disease. Clin Positron Imaging 1999; 2: 119-30.
57. Rehani MM, Sharma SK. Site of Tc-99m binding to the red blood cells. J Nuclear Medicine 1980; 22: 676-8.
58. 99m Tc-RBC SPECT study. Clin Nucl Med 2012; 37: 1041-6.
59. Pilecki S, Gierach M, Gierach J, et al. Single photon emission computed tomography (SPECT) in the diagnosis of orbital cavernous hemangioma. Pol J Radiol 2008; 73: 59-62.
60. Sharma S, Rais A, Sandhu R, Nel W, Ebadi M. Clinical significance of metallothioneins in cell therapy and nanomedicine. Int J Nanomedicine 2013; 8: 1477-88.
61. Sharma S. Nanotheranostics in Evidence Based Personalized Medicine. Curr Drug Targets 2014; 15: 915-30.
62. Villemagne VL, Ng S, Cappai R, et al. La lunga attesa: Towards a molecular approach to neuroimaging and therapeutics in Alzheimer's disease. Neuroradiol J 2006; 19: 453-74.
63. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med 2007; 13: 183-91.
64. Eckelman WC, Reba RC, Kelloff GJ. Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine. Drug Discov Today 2008; 13: 748-59.
65. Li Y, Zhang W, Wu H, Liu G. Advanced Tracers in PET Imaging of Cardiovascular Disease. Biomed Res Int 2014; 2014: 504532.
66. Cunha L, Horvath I, Ferreira S, et al. Preclinical imaging: an essential ally in modern biosciences. Mol Diagn Ther 2014; 18(2): 153-73.
67. Malaney P, Nicosia SV, Davé V. One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer Lett 2014; 344: 1-12.
68. Keunen O, Taxt T, Grüner R, et al. Multimodal imaging of gliomas in the context of evolving cellular and molecular therapies. Adv Drug Deliv Rev 2014; 76: 98-115.
69. Czernin J, Ta L, Herrmann K. Does PET/MR Imaging Improve Cancer Assessments? Literature Evidence from More Than 900 Patients. J Nucl Med 2014; 55(Suppl-2): 59S-62S.
70. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, Li X, Chen X. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010; 31: 3016-22.
71. Le Foll B, Wilson AA, Graff A, Boileau I, Di Ciano P. Recent methods for measuring dopamine D3 receptor occupancy in vivo: importance for drug development. Front Pharmacol 2014; 5: 161.
72. Hampel H, Lista S, Teipel SJ, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochem Pharmacol 2014; 88: 426-49.
73. Hargreaves RJ, Rabiner EA. Translational PET imaging research. Neurobiol Dis 2014; 61: 32-38.
74. Rossmeisl JH Jr, Garcia PA, Daniel GB, et al. Neuroimaging response assessment criteria for brain tumors in veterinary patients. Vet Radiol Ultrasound 2014; 55: 115-32.
75. van de Watering FC, Rijpkema M, Perk L, Brinkmann U, Oyen WJ, Boerman OC. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. Biomed Res Int 2014; 2014: 203601.
76. Wang C, Schroeder FA, Hooker JM. Visualizing epigenetics: current advances and advantages in HDAC PET imaging techniques. Neuroscience 2014; 264: 186-97.
77. Neuner I, Arrubla J, Felder J, Shah NJ. Simultaneous EEG-fMRI acquisition at low, high and ultra-high magnetic fields up to 9.4T: Perspectives and challenges. Neuroimage 2014; 102P1: 71-9.
78. Jupp B, Dalley JW. Behavioral endophenotypes of drug addiction: Etiological insights from neuroimaging studies. Neuropharmacology 2014; 76: 487-97.
79. Nader MA, Banks ML. Environmental modulation of drug taking: Nonhuman primate models of cocaine abuse and PET neuroimaging. Neuropharmacology 2014; 76: 510-7.
80. Gould RW, Duke AN, Nader MA. PET studies in nonhuman primate models of cocaine abuse: translational research related to vulnerability and neuroadaptations. Neuropharmacology 2014; 84: 138-51.
81. Glasser MF, Goyal MS, Preuss TM, Raichle ME, Van Essen DC. Trends and properties of human cerebral cortex: correlations with cortical myelin content. Neuroimage 2014; 93: 165-75.